2Wong NS, Anderson BO, Khoo KS, et al. Breast cancer in developing countries. Lancet, 2009, 374(9701 ) : 1567.
3Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res, 2007, 9(3) :208.
4Dean-Colomb W, Esteva FJ. Her2-posifive breast cancer: herceptin and beyond. EurJ Cancer, 2008, 44( 18 ) :2806-2812.
5Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics, 2009, 3 : 289-301.
6Milanezi F, Carvalho S, Schmitt FC. EGFB/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diag., 2008, 8(4):417-434.
7Kaufman B, Meckey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ul TANDEM study. J Clin Oncol, 2009, 5527(33 ) : 5529-5537.
8Smith I, Procter M, C.elber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369(9555) : 29-36.
9Slamon D, Eiermann W, Robert N. Phase I!I randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxombicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (rICH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat, 2005, 94 Suppl 1 : S5.
10Marry M, Cognetti F, Maraninchi D, et al. Randomized phase II trial d the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23(19): 4265-4274.
